0001104659-23-030103.txt : 20230308 0001104659-23-030103.hdr.sgml : 20230308 20230308161026 ACCESSION NUMBER: 0001104659-23-030103 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230307 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230308 DATE AS OF CHANGE: 20230308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVENUE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001644963 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474113275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38114 FILM NUMBER: 23716237 BUSINESS ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 8-K 1 tm238871d1_8k.htm FORM 8-K
0001644963 false 0001644963 2023-03-07 2023-03-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

  

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): March 7, 2023

 

Avenue Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State or Other Jurisdiction
of Incorporation)

001-38114
(Commission File Number)

 

47-4113275
(IRS Employer Identification No.)

 

 

1111 Kane Concourse, Suite 301

Bay Harbor Islands, Florida 33154

(Address of Principal Executive Offices)

 

(781) 652-4500

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act.
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
   
¨ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Class Trading Symbol(s) Name of each exchange on which registered
Common Stock ATXI Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On March 7, 2023, the Board of Directors (the “Board”) of Avenue Therapeutics, Inc. (the “Company”) voted to expand the size of the Board from five to six members, effective immediately, and appointed Alexandra MacLean, M.D., Chief Executive Officer of the Company, to the Board as a director, effective immediately, with a term expiring at the 2023 Annual Meeting of Stockholders of the Company (the “Annual Meeting”) or until her successor is elected and qualified, or, if earlier, her death, disability, resignation, disqualification or removal from the Board.

 

Dr. MacLean, due to her position of Chief Executive Officer of the Company, will not be independent under rules and regulations of the Securities and Exchange Commission (the “SEC”) and the listing requirements of The Nasdaq Stock Market and will not be permitted to sit on any of the committees of the Board. Consistent with the Company’s current policies, she will receive no compensation for her service as a director. There are no arrangements or understandings between Dr. MacLean and any other person pursuant to which Dr. MacLean was selected as a director and there are no transactions in which Dr. MacLean has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

Also on March 7, 2023, the Board appointed Jay Kranzler, M.D., Ph.D. to serve as Chairman of the Board, effective immediately, in place of Lindsay A. Rosenwald, M.D. Dr. Rosenwald will remain a member of the Board.

 

Item 5.08 Shareholder Director Nominations.

 

To the extent applicable, the information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

 

Item 8.01 Other Events.

 

2023 Annual Meeting of Stockholders

 

On March 7, 2023, the Board determined that the Annual Meeting will be held on June 22, 2023. The Board also approved April 25, 2023 as the record date for the Annual Meeting. Only stockholders of record at the close of business on that date may attend and vote at the meeting or any adjournment or postponement thereof.

 

Because the date of the Annual Meeting has changed by more than 30 days from the anniversary of the Company’s 2022 annual meeting of stockholders, the Company has set a new deadline for the receipt of stockholder proposals. In accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any stockholder proposal intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting must be delivered to, or mailed to and received at, the Company’s executive offices located at Avenue Therapeutics, Inc., 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154, Attn: David Jin, Corporate Secretary, on or before the close of business on March 24, 2023, which the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials for the Annual Meeting. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the Annual Meeting must also comply with all applicable SEC rules, including Rule 14a-8 of the Exchange Act, and the Company’s Amended and Restated Bylaws (the “Bylaws”).

 

To comply with the universal proxy rules under Rule 14a-19 of the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than May 3, 2023.

 

Under the Company’s Bylaws, stockholders may also present a proposal or director nomination at the Annual Meeting if advance written notice is timely given to the Company, in accordance with the Bylaws. Because the date of the 2023 Annual Meeting will now be held more than 30 days before the anniversary of the 2022 annual meeting of stockholders, the Company is establishing March 24, 2023 as the date by which notice by a stockholder of any such proposal or nomination must be received by the Company.

 

 

 

 

Press Release

 

On March 8, 2023, the Company issued a press release announcing (i) the expansion of the Board and appointment of Dr. MacLean to the Board and the appointment of Dr. Kranzler as Chairman of the Board, (ii) that it plans to hold the Annual Meeting of the Company on June 22, 2023, and (iii) that it will participate in a Type C meeting with the Food and Drug Administration on March 9, 2023 to discuss a proposed study protocol to assess the risk of respiratory depression related to opioid stacking on intravenous tramadol relative to an approved opioid analgesic. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

The following exhibits are furnished herewith:

 

Exhibit
Number		   Description
99.1   Press Release dated March 8, 2023
104   Cover Page Interactive Data File (embedded within Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AVENUE THERAPEUTICS, INC.
 

(Registrant)

Date: March 8, 2023

  
  By:  /s/ David Jin  
    David Jin  
    Interim Principal Financial Officer and Chief Operating Officer  

 

 

 

 

 EX-99.1 2 tm238871d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

 

Company to participate in Type C meeting for IV Tramadol with FDA on March 9, 2023

 

Miami, FL – March 8, 2023 – Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it will participate in a Type C meeting with the FDA on March 9, 2023 to discuss a proposed study protocol to assess the risk of respiratory depression related to opioid stacking on intravenous tramadol (“IV Tramadol”) relative to an approved opioid analgesic. The Company expects to provide an update on the outcome of the meeting in April 2023, after receipt of the meeting minutes from the FDA.

 

As disclosed in September 2022, Avenue received meeting minutes from the FDA regarding a Type A meeting conducted on August 9, 2022, for IV Tramadol. At the meeting, Avenue presented a study design for a single safety clinical trial that the Company believes could address the concerns regarding risks related to opioid stacking and the FDA stated that the proposed study design appeared reasonable and agreed on various study design aspects with the expectation that additional feedback would be provided to Avenue upon review of a more detailed study protocol.

 

Subsequent to the August 9 meeting, the Company incorporated the FDA’s suggestions from the meeting minutes and submitted a Type C Meeting Request and a briefing book that included a detailed study protocol for further discussion with the FDA.

 

Board Appointments

 

On March 7, 2023, Alexandra MacLean, M.D., the Chief Executive Officer of Avenue, was appointed to the Board of Directors. In addition, Jay Kranzler, M.D., Ph.D., a current Director of Avenue, was appointed as the Chairman, true to Dr. Kranzler’s expertise in the neurosciences. Lindsay Rosenwald, M.D. will remain a Director of the Company.

 

Dr. Rosenwald commented, “I am very excited to have Dr. Kranzler become Chairman of Avenue. Deep training, knowledge and experience in the neurological sciences and drug development will be very important as Avenue continues to develop and expand its portfolio.“

 

 

 

 

2023 Annual Meeting

 

Today, the Company also announced its 2023 Annual Meeting of Stockholders will be held on June 22, 2023 and that stockholders of record as of the close of business on April 25, 2023 will be entitled to notice of, and to vote at, the annual meeting and any adjournment or postponement thereof. The 2023 Annual Meeting will be a virtual meeting conducted via webcast.

 

Because the date of the Annual Meeting has changed by more than 30 days from the anniversary of the Company’s 2022 annual meeting of stockholders, the Company has set a new deadline for the receipt of stockholder proposals. In accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any stockholder proposal intended to be considered for inclusion in the Company’s proxy materials for the 2023 Annual Meeting must be delivered to, or mailed to and received at, the Company’s executive offices located at Avenue Therapeutics, Inc., 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154, Attn: David Jin, Corporate Secretary, on or before the close of business on March 24, 2023, which the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials for the 2023 Annual Meeting. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company’s proxy materials for the 2023 Annual Meeting must also comply with all applicable SEC rules, including Rule 14a-8 of the Exchange Act. To comply with the universal proxy rules under Rule 14a-19 of the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than May 3, 2023.

 

Under the Company’s Bylaws, stockholders may also present a proposal or director nomination at the Annual Meeting if advance written notice is timely given to the Company, in accordance with the Bylaws. Because the date of the 2023 Annual Meeting will now be held more than 30 days before the anniversary of the 2022 annual meeting of stockholders, notice by a stockholder of any such proposal or nomination must be provided no later than the close of business on March 24, 2023.

 

About Avenue Therapeutics

Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic and rare diseases. It is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.  

 

 

 

 

Forward-Looking Statements

This press release contains predictive or “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of current or historical fact contained in this press release, including statements that express our intentions, plans, objectives, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” “should,” “would” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations, estimates and projections made by management about our business, our industry and other conditions affecting our financial condition, results of operations or business prospects. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in, or implied by, the forward-looking statements due to numerous risks and uncertainties. Factors that could cause such outcomes and results to differ include, but are not limited to, risks and uncertainties arising from: expectations for increases or decreases in expenses; expectations for the clinical and pre-clinical development, manufacturing, regulatory approval, and commercialization of our pharmaceutical product candidate or any other products we may acquire or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable on a sustained basis; expectations or ability to enter into marketing and other partnership agreements; expectations or ability to enter into product acquisition and in-licensing transactions; expectations or ability to build our own commercial infrastructure to manufacture, market and sell our product candidate; acceptance of our products by doctors, patients or payors; our ability to compete against other companies and research institutions; our ability to secure adequate protection for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; estimates of the sufficiency of our existing cash and cash equivalents and investments to finance our operating requirements, including expectations regarding the value and liquidity of our investments; the volatility of our stock price; expected losses expectations for future capital requirements; and those risks discussed in our filings which we make with the SEC. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.

 

Contact:

Jaclyn Jaffe

Avenue Therapeutics, Inc.

(781) 652-4500

ir@avenuetx.com

 

 

 

 

 EX-101.SCH 3 atxi-20230307.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 atxi-20230307_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 atxi-20230307_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm238871d1_ex99-1img001.jpg GRAPHIC begin 644 tm238871d1_ex99-1img001.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 07, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 07, 2023
Entity File Number 001-38114
Entity Registrant Name Avenue Therapeutics, Inc.
Entity Central Index Key 0001644963
Entity Tax Identification Number 47-4113275
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1111 Kane Concourse
Entity Address, Address Line Two Suite 301
Entity Address, City or Town Bay Harbor Islands
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33154
City Area Code 781
Local Phone Number 652-4500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ATXI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm238871d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001644963 2023-03-07 2023-03-07 iso4217:USD shares iso4217:USD shares 0001644963 false 8-K 2023-03-07 Avenue Therapeutics, Inc. DE 001-38114 47-4113275 1111 Kane Concourse Suite 301 Bay Harbor Islands FL 33154 781 652-4500 false false false false Common Stock ATXI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://avenuetx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm238871d1_8k.htm atxi-20230307.xsd atxi-20230307_lab.xml atxi-20230307_pre.xml tm238871d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm238871d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm238871d1_8k.htm" ] }, "labelLink": { "local": [ "atxi-20230307_lab.xml" ] }, "presentationLink": { "local": [ "atxi-20230307_pre.xml" ] }, "schema": { "local": [ "atxi-20230307.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "atxi", "nsuri": "http://avenuetx.com/20230307", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm238871d1_8k.htm", "contextRef": "From2023-03-07to2023-03-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://avenuetx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm238871d1_8k.htm", "contextRef": "From2023-03-07to2023-03-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://avenuetx.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001104659-23-030103-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-030103-xbrl.zip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end